Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies

Table 1 Demographic and clinical data at baseline

	MCI	MCI+	MCI−	Mild AD	Mild AD+
Number of subjects (100 %)	382	206	176	97	90
Female (%)	43 %	42 %	45 %	45 %	48 %
Caucasian, n (%)	94 %	97 %	90 %	96 %	96 %
Age, yr	71.97 ± 7.39	72.97 ± 7.10	70.80 ± 7.56	75.17 ± 7.70	74.85 ± 7.66
Education, yr	16.28 ± 2.59	16.31 ± 2.62	16.25 ± 2.55	15.52 ± 2.60	15.51 ± 2.58
ApoE4 at risk,^a n (%)	177 (46 %)	142 (69 %)	35 (20 %)	67 (69 %)	65 (72 %)
MMSE	27.85 ± 1.75	27.41 ± 1.82	28.37 ± 1.52	23.19 ± 1.99	23.14 ± 1.99
CDR global	0.50 ± 0.00	0.50 ± 0.00	0.50 ± 0.00	0.77 ± 0.28	0.77 ± 0.28
CDR-SB	1.40 ± 0.84	1.56 ± 0.92	1.21 ± 0.70	4.40 ± 1.71	4.41 ± 1.65
ADAS-Cog 11	9.50 ± 4.29	10.83 ± 4.46	7.94 ± 3.50	19.66 ± 6.30	20.14 ± 6.26
ADAS-Cog 3	8.23 ± 3.76	9.43 ± 3.92	6.82 ± 3.02	15.95 ± 4.15	16.28 ± 4.12
ADAS-Cog 5	13.96 ± 6.17	16.12 ± 6.28	11.43 ± 4.99	26.20 ± 5.31	26.62 ± 5.23
ADAS-Cog 13	15.23 ± 6.68	17.52 ± 6.81	12.55 ± 5.43	29.91 ± 7.44	30.52 ± 7.35

Aβ amyloid-β, AD Alzheimer’s disease, ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, ApoE4, apolipoprotein E ε4, CDR Clinical Dementia Rating, MCI mild cognitive impairment, MMSE Mini Mental State Examination, SB Sum of Boxes
Populations enriched based on t- Tau/Aβ ratio are labelled as MCI+ and AD+. Data are presented as mean ± standard deviation unless indicated otherwise
^aApoE4 status is not available for one subject in the MCI group

ISSN: 1758-9193